| # | Security | Value | Shares | % Port | Change | Δ Shares |
|---|---|---|---|---|---|---|
| 1 | RELAY THERAPEUTICS INC COM | $169.2M | 17.00M | 9.8% | —HELD | 0 |
| 2 | ALKERMES PLC SHS | $148.5M | 4.20M | 8.6% | ADDED | +650.0K |
| 3 | ENLIVEN THERAPEUTICS INC COM | $128.4M | 3.27M | 7.4% | REDUCED | -1,417,809 |
| 4 | COGENT BIOSCIENCES INC COM | $111.2M | 2.89M | 6.4% | ADDED | +691.2K |
| 5 | SPYRE THERAPEUTICS INC COM NEW | $96.5M | 1.91M | 5.6% | REDUCED | -475,865 |
| 6 | TYRA BIOSCIENCES INC COM | $94.8M | 2.48M | 5.5% | REDUCED | -900,000 |
| 7 | CELLDEX THERAPEUTICS INC NEW COM NEW | $85.5M | 2.70M | 4.9% | ADDED | +131.6K |
| 8 | NUVALENT INC COM | $85.4M | 833.6K | 4.9% | ADDED | +283.6K |
| 9 | AMYLYX PHARMACEUTICALS INC COM | $78.5M | 5.65M | 4.5% | —HELD | 0 |
| 10 | KYMERA THERAPEUTICS INC COM | $62.5M | 750.0K | 3.6% | —HELD | 0 |
| 11 | ALTO NEUROSCIENCE INC COM SHS | $61.2M | 2.72M | 3.5% | ADDED | +900.0K |
| 12 | PHARVARIS N V COM | $54.2M | 1.92M | 3.1% | ADDED | +29.5K |
| 13 | ERASCA INC COM | $51.4M | 3.17M | 3.0% | NEW | — |
| 14 | DAMORA THERAPEUTICS INC COM NEW | $50.2M | 1.94M | 2.9% | NEW | — |
| 15 | XENON PHARMACEUTICALS INC COM | $48.0M | 825.0K | 2.8% | REDUCED | -975,000 |
| 16 | DEFINIUM THERAPEUTICS INC COM SHS | $37.8M | 2.00M | 2.2% | NEW | — |
| 17 | LB PHARMACEUTICALS INC COM SHS | $37.0M | 1.50M | 2.1% | —HELD | 0 |
| 18 | EYEPOINT INC COM NEW | $36.4M | 2.83M | 2.1% | NEW | — |
| 19 | NURIX THERAPEUTICS INC COM | $35.3M | 2.27M | 2.0% | —HELD | 0 |
| 20 | CORVUS PHARMACEUTICALS INC COM | $33.0M | 2.26M | 1.9% | NEW | — |
| 21 | ASSEMBLY BIOSCIENCES INC COM NEW | $27.8M | 1.00M | 1.6% | —HELD | 0 |
| 22 | PERSPECTIVE THERAPEUTICS INC COM NEW | $26.4M | 6.34M | 1.5% | NEW | — |
| 23 | SOLENO THERAPEUTICS INC COM | $21.8M | 652.4K | 1.3% | REDUCED | -547,568 |
| 24 | OCULAR THERAPEUTIX INC COM | $21.8M | 2.58M | 1.3% | NEW | — |
| 25 | CENTURY THERAPEUTICS INC COM | $19.7M | 8.70M | 1.1% | NEW | — |
Holdings data sourced from SEC EDGAR 13F-HR filings. Updated quarterly, approximately 45 days after quarter end. All data is public domain.
Last filed: May 15, 2026